Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis
Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
To investigate as primary objective:
- Superiority to placebo and non-inferiority to LAS106521 measured by histological clearance of one predefined target lesion;
To investigate as secondary objective:
- Superiority to LAS106521
- Improvement of treated lesions (lesion response)
- Assessment of tolerability and safety by physicians global assessment score (PGA, PGT)
- Patient's assessment of tolerability and efficacy and patient's compliance
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Altenkirchen, Germany, 57610
- Almirall Facility Site#37
-
Augsburg, Germany, 86163
- Almirall Facility Site#24
-
Augsburg, Germany, 86179
- Almirall Facility Site#23
-
Berlin, Germany, 10117
- Almirall Facility Site#01
-
Berlin, Germany, 10437
- Almirall Facility Site#28
-
Berlin, Germany, 10827
- Almirall Facility Site#02
-
Berlin, Germany, 10967
- Almirall Facility Site#34
-
Berlin, Germany, 12353
- Almirall Facility Site#35
-
Bonn, Germany, 53111
- Almirall Facility Site#31
-
Buxtehude, Germany, 21614
- Almirall Facility Site#04
-
Detmold, Germany, 32756
- Almirall Facility Site#40
-
Dresden, Germany, 01097
- Almirall Facility Site#30
-
Dülmen, Germany, 48249
- Almirall Facility Site#11
-
Düsseldorf, Germany, 40225
- Almirall Facility Site#12
-
Frankfurt, Germany, 60590
- Almirall Facility Site#17
-
Freiburg, Germany, 79104
- Almirall Facility Site#22
-
Friedrichshafen, Germany, 88045
- Almirall Facility Site#36
-
Fulda, Germany, 36037
- Almirall Facility Site#19
-
Göttingen, Germany, 37075
- Almirall Facility Site#32
-
Hamburg, Germany, 20148
- Almirall Facility Site#09
-
Jena, Germany, 07740
- Almirall Facility Site#29
-
Kiel, Germany, 24103
- Almirall Facility Site#07
-
Kiel, Germany, 24105
- Almirall Facility Site#08
-
Koblenz, Germany, 56068
- Almirall Facility Site#15
-
Landau, Germany, 76829
- Almirall Facility Site#21
-
Leipzig, Germany, 04103
- Almirall Facility Site#27
-
Lübeck, Germany, 23538
- Almirall Facility Site#06
-
Mahlow, Germany, 15831
- Almirall Facility Site#03
-
München, Germany, 80337
- Almirall Facility Site#25
-
München, Germany, 81476
- Almirall Facility Site#39
-
Nördlingen, Germany, 86720
- Almirall Facility Site#33
-
Osnabrück, Germany, 49078
- Almirall Facility Site#38
-
Pinneberg, Germany, 25421
- Almirall Facility Site#05
-
Quedlinburg, Germany, 06484
- Almirall Facility Site#26
-
Radolfzell, Germany, 78315
- Almirall Facility Site#20
-
Salzwedel, Germany, 29410
- Almirall Facility Site#10
-
Soest, Germany, 59494
- Almirall Facility Site#16
-
Vechta, Germany, 49377
- Almirall Facility Site#14
-
Wiesbaden, Germany, 65191
- Almirall Facility Site#18
-
Wuppertal, Germany, 42275
- Almirall Facility Site#13
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main Inclusion Criteria:
- Have at least 4 but not more than 10 clinically confirmed AK target lesions of mild to moderate intensity within the face/forehead or bald scalp (excluding eyelids, lips, and mucosa), i.e. actinic keratosis grade I and II according to Olsen EA et al. 1991
- Woman of childbearing potential are allowed to participate in this study only if they use a highly effective method of contraception
Main Exclusion Criteria:
- Have received effective treatment of AK in the three months preceding this clinical trial
- Have known hypersensitivity to LAS41005 or LAS106521
- Have currently other malignant or benign tumors of the skin within the treatment area (e.g. malignant melanoma, basal cell carcinoma, squamous cell carcinoma)
- Patient's taking phenytoin
- Show cornu cutaneum like alterations of the skin in the face or the bald scalp (target area)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Topical
|
|
EXPERIMENTAL: LAS41005
|
Topical
|
|
ACTIVE_COMPARATOR: LAS106521
|
Topical
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Histological status of AK target lesion
Time Frame: Day 140
|
Day 140
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Estrella Garcia, MD, MBA, Almirall Hermal GmbH
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H 1005 6002 - 0702
- EudraCT: 2007-003889-18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.